
Alberta ER doc challenges premier to come on shift, see patients wait in hallways
'It's this kind of vicarious trauma, this inability to help when we're helpers, that is causing us to leave,' Dr. Warren Thirsk said in an interview.
'Unless you experience it, you don't really get it.
'When the premier has a health emergency, do you think she's going to sit in my waiting room and wait 13 hours to be seen?
'I would challenge her to come and sit in my waiting room for 13 hours.'
Thirsk made the comments in the wake of a new survey measuring patients' experiences released late last week by the Alberta Medical Association, which represents the province's physicians.
Thirsk is the association's head of emergency medicine and works in the emergency ward of Edmonton's downtown Royal Alexandra Hospital.
He said when he arrived for a recent 6 a.m. shift, the hallway was already full of patients brought in by ambulance the night before. Some had been waiting 14 hours.
He remembers one patient with a broken hip had been there four hours and needed an operation.
This one had to be treated first. 'When I looked after that patient in the hallway with a broken hip, I had to stare into the eyes of the other 13 people down that hallway who all watched me walk up to one person and not them,' Thirsk said.
'I have the haunted stares of every other person who's looking at me, saying, 'Why aren't you in front (helping) me?''
The hip patient was seen and admitted into the hospital, he said, but then had to wait another six hours in the hallway before being moved.
Thirsk said he's seeing a trend of increasing wait times in a system that can't keep up with a provincial population now close to five million. He said he is also seeing frustration, with patients finally giving up the emergency room wait and walking out the door, potentially making their condition worse.
'They might come back the next day, or they come back by ambulance, even sicker,' he said.
The association's survey was taken by just over 1,100 Albertans. It cannot be assigned a margin of error because online surveys are not considered random samples. The survey suggests that in the last year, almost one in five patients waiting for emergency care gave up the wait and walked out instead.
Dr. Shelley Duggan, the association's president, labelled the numbers 'disturbing' and attributed them to many factors: lack of specialists; patients left in hospital because of no room in continuing care; and not enough family doctors.
'It's a very complex issue - it's not just one simple fix,' Duggan said in an interview.
Duggan said their survey reflects national challenges that aren't unique to Alberta, and although most patients are satisfied with their care when they can get it, access here remains a 'huge problem.'
The Alberta government disputes the survey's numbers, saying they don't reflect broader health data. The province says the percentage of those leaving the ER without being seen is around 10 per cent in Alberta's top 16 hospitals.
Kyle Warner, press secretary to Hospital Services Minister Matt Jones, said only two hospitals saw one in five patients leaving the ER early.
'Delays in Alberta's ED are shorter than in other large provinces and we are one of the top performers in the country — but that's still not good enough," Warner said in an emailed statement. 'We know there is more work to do, and we continue to focus on recruitment.'
Numbers published by Health Quality Alberta, the agency that gathers data for the province, show the number of people who leave before being seen varies depending on the hospital. At Royal Alexandra Hospital, it was as high as almost 22 per cent per cent of patients last fall. At Foothills Medical Centre in Calgary, the average was eight per cent.
But across the board, that number has crept higher than it was in 2020, even in medium-sized urban hospitals like Northern Lights Regional in Fort McMurray, where the average was 5.6 per cent late last year.
NDP Opposition health critic Sarah Hoffman said in a statement it's unacceptable that so many Albertans are without a family doctor and that emergency room wait times remain dangerously high.
'Despite a promise to improve the system, Danielle Smith's UCP government has only deepened the chaos,' said Hoffman.
This report by The Canadian Press was first published July 7, 2025.
Lisa Johnson, The Canadian Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
an hour ago
- National Post
Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia
Article content SMITHS FALLS, Ontario — Canopy Growth Corporation ('Canopy Growth' or the 'Company') (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company's medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Article content Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES' top performing flower strains in the Canadian medical and adult-use cannabis markets. Jack Frost, a cross of White Widow and Cold Creek Kush, adds further genetic depth to the lineup. Both strains are initially available in 10g flower formats. Article content 'Adding 7ACRES to our Australian portfolio helps ensure patients and prescribers have access to a diverse range of high-quality flower options,' said Andrew Bevan, SVP, Global Medical. 'With recent improvements to our global supply chain, we're positioned to deliver these strains with consistent quality and reliable access to patients in Australia.' Article content 'Global medical is one of Canopy Growth's largest commercial opportunities,' said Luc Mongeau, Chief Executive Officer. 'Our ability to scale high-quality production in Canada and reliably supply international markets remains a key strength as we expand our global medical platform.' Article content The introduction of 7ACRES complements Canopy Growth's existing presence in Australia, which includes Tweed flower products as well as Spectrum Therapeutics oils available in Red, Yellow, White, and Blue formulations. Together, this expanded medical portfolio reflects Canopy Growth's focus on building a scalable medical platform across international markets. Article content About Canopy Growth Article content Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Article content Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Article content Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ('Canopy USA'). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology. Article content At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer. Article content Article content Article content Article content Contacts Article content


Globe and Mail
an hour ago
- Globe and Mail
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025

National Post
an hour ago
- National Post
Satellos to Present at Canaccord Genuity's 45th Annual Growth Conference
Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the Canaccord Genuity's 45th Annual Growth Conference, taking place Aug. 13–14, 2025, at the InterContinental Boston. Article content Satellos management will present on Wed., Aug. 13, from 12:30 to 12:55 p.m. ET in Abigail Adams C and will participate in one-on-one meetings during the conference. Article content Article content Canaccord Genuity's 45th Annual Growth Conference Article content Format: Presentation and Article content webcast Article content Article content Date: Wed., Aug. 13 Article content Article content Time: 12:30 p.m. ET Article content Article content Location: InterContinental Boston Article content The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation. Article content About Satellos Bioscience Inc. Article content Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment, starting with DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Investors: Article content Liz Williams, CFO, Article content ir@ Article content Article content Media: Article content Article content